Summary
The relationship between erbB-2 oncoprotein overexpression and hormone receptors in breast cancer is controversial. Of 320 infiltrating carcinomas, 75 (23%) showed membranous positivity for erbB-2 protein using CB-11 antibody, with 31 (9.7%) strongly positive. Estrogen and progesterone receptors, determined by both biochemical and immunohistochemical assays, were negative more often in strongly erbB-2 positive tumors, or were positive at lower amounts, than in 56 tumors devoid of CB-11 staining. Strong erbB-2 positivity also correlated with lower patient age, higher histopathologic tumor grade, and higher S phase fraction, but not with tumor size, lymph node involvement, or DNA aneuploidy. Thirty-three lobular carcinomas showed strong erbB-2 positivity as frequently as the overall group (9.1%). Cytoplasmic CB-11 positivity without membrane positivity, thought not to correlate with true erbB-2 positivity, was observed in 189 (59%) tumors with a slight (1–2 +) reaction in 124 (39%) tumors and a moderate-to-strong (3–4 +) reaction in 65 (20%) tumors. Moderate-to-strong cytoplasmic positivity correlated with higher histopathologic grade and negativity for immunohistochemical, but not biochemical, hormone receptors. CB-11 cytoplasmic positivity may have biological significance.
References
McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. New Engl J Med 326: 1756–1761, 1992
Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Sem Cancer Biol 4: 19–26, 1993
Gullick WJ: The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer; suppl 5: 55–61, 1990
Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, Gullick WJ, Tuzi NL, May FEB, Westley BR, Horne CHW: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161: 15–25, 1990
Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, Kiang DT, Strickler JG: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23: 1141–1150, 1992
De Potter CR, Van Daele S, Van De Vijver MJ, Pauwels C, Maertens G, DeBoever J, Vandekerckhove D, Roels H: The expression of theneu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathol 15: 351–362, 1989
Adnane J, Gaudray P, Simon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C: Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4: 1389–1395, 1989
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989
Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989
Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, Huber J, Zielinski C, Reiner G, Jakesz R, Staffen A, Reiner A, Wrba F, Spona J: HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4: 109–114, 1989
Garcia I, Dietrich P-Y, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49: 6675–6679, 1989
Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332–4337, 1990
Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114: 160–163, 1990
Marx D, Schauer A, Reiche C, May A, Ummenhofer L, Reles A, Rauschecker H, Sauer R, Schumacher M: c-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15–20, 1990
Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Faucett C, Niland J: Immunohistochemical assay ofneu/c-erbB-2 oncogene product in paraffin-embedded tissue in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 4: 466–474, 1991
Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H:ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6: 137–143, 1991
Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991
Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, Sorvillo JM: Expression ofneu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer: correlation with clinicopathologic parameters. Am J Pathol 138: 1527–1534, 1991
Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression ofin situ invasive breast cancer. Hum Pathol 23: 974–979, 1992
Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA: Prevalence of amplification of the oncogenes c-myc, HER2/neu andint-2 in one thousand human breast tumors: correlation with steroid receptors. Eur J Cancer 28: 697–700, 1992
Ciocca DR, Fujimara FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, McGuire WL: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Nat Cancer Inst 84: 1279–1282, 1992
Lampe B, Genz T, Maassen V, Mikorey S, Klosterhalfen T: Correlation of cerbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors. Arch Gynecol Obstet 251: 45–50, 1992
Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL: Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 12: 1965–1972, 1992
Heatley M, Maxwell P, Whiteside C, Toner PG: c-erbB-2 oncogene product expression depends on tumor type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Path Res Pract 189: 261–266, 1993
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987
Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor shortterm prognosis. Oncogene 1: 423–430, 1987
Ro J, El-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G: c-erbB-2 amplification in nodenegative human breast cancer. Cancer Res 49: 6941–6944, 1989
Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M: c-erbB-2 andras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833–838, 1991
Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991
McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991
Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447–450, 1991
Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P: P53 and c-erbB-2 protein expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98: 408–418, 1992
Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448–452, 1988
Lacroix H, Iglehart JD, Skinner MA, Kraus MH: Overexpression oferbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145–151, 1989
Zhou D-J, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105–108, 1989
Uehara T, Kaneko Y, Kanda N, Yamamoto T, Higashi Y, Nomoto C, Izumo T, Takayama S, Sakurai M: c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. Jpn J Cancer Res 81: 620–624, 1990
Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944–948, 1991
Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut M-N, Allasia C, Piana L: Expression of HER-2/neu oncogene in breast cancer: correlation of quantitative immunocytochemistry and prognostic factors. Int J Oncol 1: 815–823, 1992
Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10: 686–695, 1992
Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA, Preisler HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 52: 2597–2602, 1992
Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12: 419–426, 1992
Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L, Parwaresch R: Amplification of c-myc but not of c-erbB-2 is associated with high proliferation capacity in breast cancers. Cancer Res 53: 1956–1961, 1993
Bloom HJG, Richardson WW: Histologic grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377, 1957
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19: 403–410, 1991
Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJW, Angus B, Horne CHW: Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163: 105–110, 1991
Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y: c-erbB-2 oncoprotein expressionversus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69: 2953–2960, 1992
Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, De Lena M: Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res 11: 1395–1400, 1991
Baak JPA, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS: Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64: 215–223, 1991
Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044–1048, 1992
Soomro S, Shousha S, Taylor P, Shepard HM, Feldmann M: c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 44: 211–214, 1991
Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: c-erbB-2 oncogene protein inin situ and invasive lobular breast neoplasia. Cancer 68: 331–334, 1991
Somerville JE, Clarke LA, Biggart JD: c-erbB-2 overexpression and histological type ofin situ and invasive breast carcinoma. J Clin Pathol 45: 16–20, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keshgegian, A.A. ErbB-2 oncoprotein overexpression in breast carcinoma: Inverse correlation with biochemically- and immunohistochemically-determined hormone receptors. Breast Cancer Res Tr 35, 201–210 (1995). https://doi.org/10.1007/BF00668210
Issue Date:
DOI: https://doi.org/10.1007/BF00668210